CTLT has been the subject of several other reports. Royal Bank of Canada reduced their price target on Catalent from $58.00 to $55.00 and set an “outperform” rating for the company in a report on Thursday. Robert W. Baird upgraded shares of Catalent from a “neutral” rating to an “outperform” rating and lifted their price target for the company from $45.00 to $53.00 in a research report on Thursday. Deutsche Bank Aktiengesellschaft raised their price objective on Catalent from $37.00 to $45.00 and gave the company a “hold” rating in a research note on Tuesday, August 15th. Bank of America lifted their price objective on Catalent from $39.00 to $46.00 and gave the stock an “underperform” rating in a report on Thursday, August 31st. Finally, Wells Fargo & Company reduced their price objective on Catalent from $50.00 to $42.00 and set an “equal weight” rating for the company in a report on Thursday. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $50.45.
Catalent Stock Up 0.3 %
Catalent (NYSE:CTLT – Get Free Report) last issued its quarterly earnings results on Wednesday, November 15th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.04. Catalent had a positive return on equity of 1.54% and a negative net margin of 22.36%. The firm had revenue of $982.00 million during the quarter, compared to the consensus estimate of $939.62 million. During the same period last year, the company earned $0.25 earnings per share. The company’s revenue for the quarter was down 3.9% on a year-over-year basis. Sell-side analysts predict that Catalent will post 0.61 EPS for the current year.
In related news, insider John J. Greisch acquired 21,000 shares of the company’s stock in a transaction dated Wednesday, August 30th. The stock was bought at an average price of $50.24 per share, with a total value of $1,055,040.00. Following the purchase, the insider now directly owns 34,000 shares in the company, valued at approximately $1,708,160. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other news, Director Michelle R. Ryan purchased 1,000 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was bought at an average cost of $49.98 per share, for a total transaction of $49,980.00. Following the completion of the purchase, the director now directly owns 1,979 shares of the company’s stock, valued at approximately $98,910.42. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John J. Greisch purchased 21,000 shares of the stock in a transaction that occurred on Wednesday, August 30th. The stock was bought at an average price of $50.24 per share, with a total value of $1,055,040.00. Following the completion of the acquisition, the insider now owns 34,000 shares in the company, valued at approximately $1,708,160. The disclosure for this purchase can be found here. Insiders sold a total of 3,553 shares of company stock valued at $158,329 in the last 90 days. 0.58% of the stock is currently owned by insiders.
Institutional Trading of Catalent
Several large investors have recently added to or reduced their stakes in the stock. Jacobs Levy Equity Management Inc. acquired a new stake in Catalent in the 3rd quarter valued at $935,000. Tudor Investment Corp Et Al acquired a new stake in Catalent during the 3rd quarter valued at $296,000. Toroso Investments LLC acquired a new stake in Catalent during the 3rd quarter valued at $420,000. The Manufacturers Life Insurance Company grew its holdings in Catalent by 4.0% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 763,972 shares of the company’s stock valued at $34,784,000 after purchasing an additional 29,594 shares in the last quarter. Finally, Royal London Asset Management Ltd. grew its holdings in Catalent by 1.0% during the 3rd quarter. Royal London Asset Management Ltd. now owns 60,686 shares of the company’s stock valued at $2,764,000 after purchasing an additional 615 shares in the last quarter.
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
- Five stocks we like better than Catalent
- What Investors Need to Know to Beat the Market
- 3 large caps with red hot RSIs with upside
- 3 Tickers Leading a Meme Stock Revival
- Johnson Controls International: Nothing but upside for investors
- How to Effectively Use the MarketBeat Ratings Screener
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.